Lv3
250 积分 2023-05-25 加入
Twenty‐year outcome of prevalence, incidence, mortality and survival rate in patients with malignant bone tumors
3天前
已完结
Discovery of Darovasertib (NVP-LXS196), a Pan-PKC Inhibitor for the Treatment of Metastatic Uveal Melanoma
24天前
已完结
Neoadjuvant Checkpoint Immunotherapy and Melanoma: The Time Is Now
27天前
已完结
Uveal Melanoma Treatment: An Update
27天前
已完结
Treatment Patterns and Real-World Outcomes of Molecular Subgroups in Patients With AML Receiving Frontline Venetoclax-Based Therapy
1个月前
已关闭
Mechanisms of Clinical Resistance to Selective FGFR2 Inhibition by Lirafugratinib
1个月前
已关闭
Isocitrate Dehydrogenase Mutations in Cancer: Mechanisms of Transformation and Metabolic Liability
1个月前
已完结
Lenvatinib plus checkpoint inhibitors in patients (pts) with advanced intrahepatic cholangiocarcinoma (ICC): Preliminary data and correlation with next-generation sequencing
2个月前
已关闭
Research Spotlight
2个月前
已关闭
Recent advances in molecular classification and multimodal treatment of intrahepatic cholangiocarcinoma
2个月前
已关闭
皖公网安备34019202002308
